Mary Caffrey

Due to unprecedented disruption and missed screenings during the pandemic, efforts to implement a 5-year performance period under the Radiation Oncology Model were extended twice.

When the sympathetic nervous system is unregulated, it can lead to high blood pressure and elevated heart rate.

The dialysis company faces a $100M fine for each of 2 antitrust counts.

The new standards come as community oncology practices await word on the future of the oncology care model, which will expire in 2022.

A statement from the makers of the SGLT2 inhibitor empagliflozin suggests the benefits in heart failure with preserved ejection fraction (HFpEF) are significant.

Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.

Abstracts cover the cost of cancer-related diarrhea, 30-day readmission rates, and how perceptions of the likelihood of survival affect end-of-life care.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), outlines why updates were made to the ADA’s Living Standards of Care.

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the benefits of sotagliflozin for individuals with type 2 diabetes and chronic kidney disease or heart failure.

The study was launched the same month as the first US approval of a sodium-glucose co-transporter 2 inhibitor, and the failure to include a drug from this class was viewed by a commentator as a weakness of GRADE.

Sanofi gave up rights to develop the glucagon-like peptide 1 receptor agonist last year after a change in strategy.

How therapeutic advances can address all 3 conditions was the topic of a symposium Friday during the 81st Scientific Sessions of the American Diabetes Association (ADA), “The Intersection of Diabetes, Heart Failure and Kidney Disease: Challenges and New Insights.”

The once-weekly therapy is also being studied in nonalcoholic steatohepatitis and heart failure with preserved ejection fraction and obesity.

Updates reflect the increased intersection among diabetes, cardiovascular, and kidney disease care among certain drug classes, especially sodium glucose co-transporter 2 (SGLT2) inhibitors.

The American Diabetes Association's chief scientific and medical officer said the results are important to families at risk of type 1 diabetes.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA) offers insights on trial results and sessions to be presented at this year's ADA Scientific Sessions, taking place virtually June 25-29, 2021.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), previews sessions to be presented at the ADA's 81st Scientific Sessions.

The study's lead author said researchers have searched for a generation for an effective therapy to give to high-risk patients with renal cell carcinoma after initial surgery for the tumor.

Also, phase 2 results for atezolizumab presented during the 2021 Annual Meeting of the American Society of Clinical Oncology could help patients in same setting who need another option.

Biomarker testing and remote patient monitoring are just 2 areas of research presented during the annual meeting of the American Society of Clinical Oncology (ASCO).

Equality in cancer care is not sufficient, said Lori Pierce, MD, FASTRO, FASCO, a radiation oncologist from the University of Michigan and president of the American Society of Clinical Oncology (ASCO). Equity—which means that patients have similar outcomes, regardless of circumstance—is harder to achieve.

During the first day of the 2021 Annual Meeting of the American Society of Clinical Oncology, a discussion on disparities in women's cancer care highlighted challenges in the United States and overseas.

ASCO officials characterized the results as practice changing and said they highlighted the need for genetic testing in patients who receive a diagnosis of high-risk breast cancer.